Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BackgroundCovid-19 morbidity and mortality are associated with a dysregulated immune response. Tools are needed to enhance existing immune profiling capabilities in affected patients. Here we aimed to develop an approach to support the design of targeted blood transcriptome panels for profiling the immune response to SARS-CoV-2 infection.MethodsWe designed a pool of candidates based on a pre-existing and well-characterized repertoire of blood transcriptional modules. Available Covid-19 blood transcriptome data was also used to guide this process. Further selection steps relied on expert curation. Additionally, we developed several custom web applications to support the evaluation of candidates.ResultsAs a proof of principle, we designed three targeted blood transcript panels, each with a different translational connotation: immunological relevance, therapeutic development relevance and SARS biology relevance.ConclusionAltogether the work presented here may contribute to the future expansion of immune profiling capabilities via targeted profiling of blood transcript abundance in Covid-19 patients.

More information Original publication

DOI

10.1186/s12967-020-02456-z

Type

Journal article

Publication Date

2020-07-01T00:00:00+00:00

Volume

18

Addresses

S, i, d, r, a, , M, e, d, i, c, i, n, e, ,, , D, o, h, a, ,, , Q, a, t, a, r, .

Keywords

Immune System, Humans, Pneumonia, Viral, Coronavirus Infections, Antibodies, Viral, Gene Expression Profiling, Internet, Software, Adult, Pandemics, Transcriptome, Betacoronavirus, RNA-Seq, COVID-19, SARS-CoV-2